Abstract
Perrine Janiaud, PhD; Cathrine Axfors, MD, PhD; Andreas M. Schmitt, MD; Viktoria Gloy, PhD; Fahim Ebrahimi, MD, MSc; Matthias Hepprich, MD; Emily R. Smith, ScD, MPH; Noah A. Haber, ScD; Nina Khanna, MD; David Moher, PhD; Steven N. Goodman, MD, PhD; John P. A. Ioannidis, MD, DSc; Lars G. Hemkens, MD, MPH
Highlights
Related article page 1185 from 6 randomized clinical trials (RCTs) (5 published as preprints and 1 as a press release), the authors found that treatment with convalescent plasma vs placebo or standard of care was not associated with a significant decrease in all-cause mortality
[95% CI, 0.92-1.12] for all 10 RCTs) or with benefit for other clinical outcomes, including length of hospital stay, mechanical ventilation use, and clinical improvement or deterioration
In August 2020, the US Food and Drug Administration (FDA) granted an Emergency Use Authorization for convalescent plasma based on observational data
Summary
In this issue of JAMA, Janiaud et al[1] present a meta-analysis of randomized clinical trials (RCTs) of convalescent plasma for the treatment of patients with COVID-19. Challenges for COVID-19 Research in the US The great scientific achievement of 2020 was the development, testing, and approval of numerous vaccines in less than 1 year.[2] The US had a major role in this effort, both regarding the basic science discoveries and the conduct of clinical trials.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
